Media ReleasesSienna Cancer Diagnostics

View All Sienna Cancer Diagnostics News

Sienna Cancer Diagnostics and Minomic Enter Collaboration Agreement

Sienna and Minomic Enter Collaboration Agreement to Develop Pancreatic Cancer Test

  • Pancreatic cancer is the most lethal cancer in humans, with a 5-year survival rate of less than 10%.
  • There are no liquid biopsy assays for the early detection of pancreatic cancer.
  • There is independent evidence that the protein GPC-1 on exosomes is strongly elevated in the blood from pancreatic cancer patients.
  • Sienna will utilise its proprietary EXO-NETTM exosome capture technology to isolate exosomes, and Minomic will use its proprietary anti-GPC-1 antibody in a pilot study to test the feasibility of developing a proprietary pancreatic cancer assay.

Melbourne, Australia, 30 October 2019: Sienna Cancer Diagnostics Ltd (ASX: SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative cancer- related tests, has entered into a research collaboration agreement with Sydney-based Minomic International Ltd, to develop a proprietary test for the early detection of pancreatic cancer.

For further information please download the attached PDF: Download this document